Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
New words:
AA, AB, Abbott, abstraction, academia, accomplishment, Adalattm, addingTysabrito, adhesion, aggressively, AIB, Allergy, Allied, ambulatory, Amerisource, AmerisourceBergen, Ando, andPrialt, antibacterial, approvedPrialtfor, arm, Armenia, arrive, ascending, Avinzatm, Azactamlost, Bachelor, baseline, Bergen, bifurcation, binomial, bioavailability, Bond, borne, broader, byTysabri, Cardinal, career, catalyze, CBE, CD, CDAI, CEO, characteristic, charitable, Chemistry, chosen, closest, cohabitation, Color, Colorado, commercializeTysabri, commercializeTysabriand, comparison, concentrated, concentration, Congo, consignment, construction, continental, convenient, Cornell, coveringMaxipime, coveringMaxipimeexpire, coveringPrialtmay, Cranfield, crystalline, culminating, daily, Dale, DDW, debilitating, Democratic, demurring, desired, devastating, developingTysabri, developingTysabrifor, dexmethylphenidate, dissolution, divestiture, Doctor, drove, ease, edition, EDT, education, element, elevated, EMEA, Emisphere, ENCORE, Endocrine, England, environment, ES, ethambutal, evaluateTysabriin, excise, ExcludingTysabri, expansion, explained, extensiveTysabrisafety, factor, Fellow, fewer, FileNo, Focalin, forAzactamexpired, forgivable, forgiven, forMaxipimeandAzactam, forMaxipimeandAzactamin, forPrialtfor, forTysabri, forTysabricovering, forTysabrifor, forTysabrito, forum, foundation, freedom, fromTysabriamounted, fromTysabriin, Frovatm, gadolinium, Galway, Gary, gather, genericAzactamproduct, genericization, growing, gut, healed, histopathology, historicalForm, hope, hoped, hybrid, Hyperactivity, iBoxx, immunogenicity, immunosuppressant, ImpactRX, includingTysabri, incorporatingNanoCrystaltechnology, incorrectly, indemnification, indemnify, Index, indicted, influential, infrequent, inPopular, insignificant, Inspector, integrin, intelligent, internationally, intravenousTysabriin, invade, involuntary, Iomai, ISOA, Johnson, journal, Kennedy, keyNanoCrystaltechnology, kind, lag, Lauder, launchedPrialtin, launchingPrialtduring, leg, lengthen, lump, Lurker, makingTysabrithe, Manual, manufacturesTysabri, manufacturingTysabriexpire, marketingTysabri, Maxipimerevenue, MBA, McKesson, Megace, mental, Miami, Middlesex, military, misfolded, Myambutoltm, Nancy, NanoCrystaltechnology, NE, neurobiology, ninety, noAzactamgeneric, nociceptive, Nortel, NUI, ofAzactam, ofAzactamtotalled, ofAzactamwill, ofMaxipime, ofMaxipimeandAzactam, ofMaxipimeandAzactaminventory, ofMaxipimeare, ofPrialtin, ofPrialtto, ofPrialttotalled, ofTysabriamounted, ofTysabriand, ofTysabriandPrialt, ofTysabriclinical, ofTysabridosing, ofTysabrifor, ofTysabriin, ofTysabriled, ofTysabrimonotherapy, ofTysabrion, ofTysabriover, ofTysabritherapy, ofTysabrito, onAzactam, onAzactamexpired, onForm, onPrialtachieving, onTysabri, opportunity, opposition, ourNanoCrystaldrug, ournanocrystaltechnology, ourTysabricollaboration, particle, patentedNanoCrystaltechnology, payer, persuasive, Pharmacology, philanthropy, pioneered, pleading, pool, Postdoctoral, potency, Pramod, predominantly, prepayment, prescribeMaxipimefor, productAzactamlost, productsMaxipimeandAzactam, prolonged, prompt, promulgated, protocol, proud, PTO, pump, purchaseTysabrifrom, quash, receivingTysabriin, reclassed, reconstitution, recordkeeping, reformulation, refrigerated, regardingTysabri, regardingTysabriculminated, reintroduceTysabrito, rely, remote, rent, Reseller, rest, retail, Rheumatology, RitalinLAtm, Roche, Rockefeller, rollforward, roof, RSU, running, SA, satisfactorily, sBLA, Schenk, schizophrenia, score, sellingPrialtin, shelf, shipment, showedTysabrimaintained, Skelaxintm, Sonatatm, space, span, Specialist, spending, Srivastava, stop, stream, Sudan, sued, summary, supplier, surface, Susquehanna, Ted, Temple, thatAzactamwill, thatTysabri, thatTysabribe, theNew, thePrialt, thePrialtEuropean, theTysabri, theTysabriand, theTysabricommercial, theTysabrivoluntary, thisform, threatened, timeline, Timetable, toAzactamwill, toMaxipimeandAzactam, toMaxipimefrom, tookTysabriand, topline, toPrialtto, toRule, toTysabri, toTysabriin, toTysabriintellectual, Tribunal, UC, unanimously, undelivered, unique, unmet, unused, unvested, upheld, upper, Uzbekistan, vast, vendor, venue, Villanova, volume, Wellesley, withMaxipimeandAzactamin, withMaxipimeduring, withTysabri, withTysabriin, withTysabrior, withTysabriwhen, worth, wound, wrongful, XR, Yednock, youth, zaleplon, Zanaflextm, Zonegrantm
Removed:
communicated, Dilution, Display, Enzon, indenture, Monarch, processed, regular
Filing tables
Filing exhibits
- 20-F Annual report (foreign)
- 2 Exhibit 2.(B)(6)
- 4 Exhibit 4.(C)(5)
- 4 Exhibit 4.(C)(8)
- 4 Exhibit 4.(C)(11)
- 4 Exhibit 4.(C)(13)
- 4 Exhibit 4.(C)(14)
- 4 Exhibit 4.(C)(15)
- 4 Exhibit 4.(C)(16)
- 8.1 Exhibit 8.1
- 12.1 Exhibit 12.1
- 12.2 Exhibit 12.2
- 13.1 Exhibit 13.1
- 13.2 Exhibit 13.2
- 15.1 Exhibit 15.1
- 15.2 Exhibit 15.2
Elan similar filings
Filing view
External links
Exhibit 15.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Board of Directors
Elan Corporation, plc
Dear Sirs:
We consent to incorporation by reference in the Post-Effective Amendments onForms F-3 andS-8 to the Registration Statement onForm F-4(No. 333-12756) of Elan Corporation, plc, the Registration Statement onForm F-4(No. 333-128234) of Elan Finance Public Limited Company and Elan Finance Corp., the Registration Statements onForm S-8 (Nos.333-13996,333-12344,333-11940,333-09644,333-09284,333-09048,333-08384,333-07361,333-07136,333-14240,333-27506,333-100252 and333-121021) of Elan Corporation, plc, and the Registration Statement onForm F-3(No. 333-13130) of Elan Corporation, plc and Athena Neurosciences Finance, LLC, of our report dated March 28, 2006, relating to the consolidated balance sheets of Elan Corporation, plc and subsidiaries as of December 31, 2005 and 2004 and the related consolidated statements of operations, shareholders’ equity and other comprehensive income/(loss) and cash flows for each of the years in the three year period ended December 31, 2005 and related financial statement schedule, which report appears in theForm 20-F of Elan Corporation, plc for the fiscal year ended December 31, 2005.
/s/ KPMG
KPMG
Dublin, Ireland
March 28, 2006